FOLH1 and neoplasm: Emerging biomarkers include cell-free (cf) DNA epigenomic signals at the FOLH1 (PSMA) locus: acting as a surrogate for tumour PSMA expression, correlated highly with total-tumour PSMA-PET/CT SUVmean (p < 0.05), and was potentially a predictive biomarker of therapeutic response [45].